5-alpha reductase inhibitor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

5-alpha reductase inhibitor

A medication to treat benign prostatic hyperplasia. It blocks the conversion of testosterone to dihydrotestosterone.
See also: inhibitor
References in periodicals archive ?
In the haste of today's busy medical practices, we are concerned that huge numbers of men who could benefit enormously from 5-alpha reductase inhibitors will not be prescribed them.
"That body of evidence provided proof" that the 5-alpha reductase inhibitors will decrease the risk of prostate cancer in men being regularly screened for the disease, Dr.
All three of the molecules below are 5-alpha reductase inhibitors and prevent testosterone from converting to DHT, the "bad" form of testosterone that causes baldness and prostate issues
Using data from the National Health and Nutrition Examination Survey (NHANES) for 2003-2006, the researchers assessed associations between medication use and log-transformed PSA levels in 1,846 men aged 40 years or older who had a serum PSA measurement; did not have a history of prostate cancer, prostatitis, or recent prostate manipulation; and were not taking 5-alpha reductase inhibitors or hormone therapy.
5-alpha reductase inhibitors (5-ARIs): These drugs halt the advance of BPH by shrinking the prostate, and are particularly beneficial for men with larger prostates.
In discussing implementation of initial or simple treatments we are referring to behavioural therapy, pharmacologic therapy (e.g., alpha-blockers, 5-alpha reductase inhibitors, antimuscarinics) and physiotherapy.
Men were asked to take one of the 5-alpha reductase inhibitors or a placebo in a double-blind, randomized, controlled study over a number of years.
In the treatment of benign prostatic hyperplasia (BPH), there are several widely utilized medical therapies such as alpha-blockers and 5-alpha reductase inhibitors and occasionally antimuscarinics that have become standard therapies in the clinical practice guidelines.
Food and Drug Administration's (FDA) Oncologic Drug Advisory Committee (ODAC) recommended against prostate cancer chemoprevention labelling for the 5-alpha reductase inhibitors (5ARIs).
A Finasteride (Proscar) and dutasteride (Avodart) belong to a class of drugs known as 5-alpha reductase inhibitors (5-ARIs).
Repeat at age 45 if initial PSA is <1.0 ng/mL, and annually for men with PSA [greater than or equal to] 1.0 ng/mL or higher or a family history, African-Americans, or men taking 5-alpha reductase inhibitors (Proscar, Propecia, and Avodart).
Second, the Food and Drug Administration (FDA) ruled against the use of 5-alpha reductase inhibitors (ARIs) for prostate cancer prevention, largely due to concerns about an increase in high-grade cancer.[sup.2]

Full browser ?